CD274 and neoplasm: Clinical management options for TNBC remain limited, despite relatively high TIL numbers [16–18], PD-L1 expression [19–21] and tumor mutational burden [22, 23] compared with other subtypes, and multiple clinical trials have focused on targeting TNBC [16, 20, 22, 23, 121–124].